{"id":59039,"date":"2026-06-09T07:27:17","date_gmt":"2026-06-09T07:27:17","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/59039\/"},"modified":"2026-06-09T07:27:17","modified_gmt":"2026-06-09T07:27:17","slug":"gsk-to-buy-nuvalent-maker-of-targeted-cancer-drugs-for-10-6b","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/59039\/","title":{"rendered":"GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B"},"content":{"rendered":"

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.<\/p>\n

LONDON \u2014 GSK said Tuesday it would buy the cancer-focused biotech Nuvalent in a deal worth $10.6 billion, as the British firm continues its expansion in oncology.<\/p>\n

The deal is the latest in a run of biopharma acquisitions in recent months, as large and even midsize companies have been looking to bolster their pipelines as some of their key products face looming generic competition. The GSK-Nuvalent deal is one of the largest in the recent buying spree, and GSK\u2019s largest in years.<\/p>\n

GSK is paying $124 per share for Cambridge, Mass.-based Nuvalent, a 26% premium to the biotech\u2019s average share price over the last 30 days. With the cash acquired through the deal, GSK is spending about $9.4 billion on the pickup.\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…\n","protected":false},"author":2,"featured_media":47920,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[1852,11314,20785,2029,20102],"class_list":["post-59039","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-cancer","tag-drug-development","tag-gsk","tag-pharmaceuticals","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116718970046886959","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/59039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=59039"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/59039\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/47920"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=59039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=59039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=59039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}